Literature DB >> 17592015

The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis.

Mohammed S Razzaque1, Beate Lanske.   

Abstract

Normal mineral ion homeostasis is tightly controlled by numerous endocrine factors that coordinately exert effects on intestine, kidney, and bone to maintain physiological balance. The importance of the fibroblast growth factor (FGF)-23-klotho axis in regulating mineral ion homeostasis has been proposed from recent research observations. Experimental studies suggest that 1) FGF23 is an important in vivo regulator of phosphate homeostasis, 2) FGF23 acts as a counter regulatory hormone to modulate the renal 1alpha-hydroxylase and sodium-phosphate cotransporter activities, 3) there is a trend of interrelationship between FGF23 and parathyroid hormone activities, 4) most of the FGF23 functions are conducted through the activation of FGF receptors, and 5) such receptor activation needs klotho, as a cofactor to generate downstream signaling events. These observations clearly suggest the emerging roles of the FGF23-klotho axis in maintaining mineral ion homeostasis. In this brief article, we will summarize how the FGF23-klotho axis might coordinately regulate normal mineral ion homeostasis, and how their abnormal regulation could severely disrupt such homeostasis to induce disease pathology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17592015      PMCID: PMC2900827          DOI: 10.1677/JOE-07-0095

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  62 in total

1.  FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.

Authors:  Takashi Shimada; Hisashi Hasegawa; Yuji Yamazaki; Takanori Muto; Rieko Hino; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  J Bone Miner Res       Date:  2003-12-29       Impact factor: 6.741

2.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

3.  FGF-23 in patients with end-stage renal disease on hemodialysis.

Authors:  Yasuo Imanishi; Masaaki Inaba; Kiyoshi Nakatsuka; Kyoko Nagasue; Senji Okuno; Asami Yoshihara; Masakazu Miura; Akimitsu Miyauchi; Keisuke Kobayashi; Takami Miki; Tetsuo Shoji; Eiji Ishimura; Yoshiki Nishizawa
Journal:  Kidney Int       Date:  2004-05       Impact factor: 10.612

4.  FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa.

Authors:  Takashi Shimada; Itaru Urakawa; Yuji Yamazaki; Hisashi Hasegawa; Rieko Hino; Takashi Yoneya; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Biochem Biophys Res Commun       Date:  2004-02-06       Impact factor: 3.575

5.  Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis.

Authors:  Orit Topaz; Daniel L Shurman; Reuven Bergman; Margarita Indelman; Paulina Ratajczak; Mordechai Mizrachi; Ziad Khamaysi; Doron Behar; Dan Petronius; Vered Friedman; Israel Zelikovic; Sharon Raimer; Arieh Metzker; Gabriele Richard; Eli Sprecher
Journal:  Nat Genet       Date:  2004-05-09       Impact factor: 38.330

6.  FGF23 is processed by proprotein convertases but not by PHEX.

Authors:  Anna Benet-Pagès; Bettina Lorenz-Depiereux; Hans Zischka; Kenneth E White; Michael J Econs; Tim M Strom
Journal:  Bone       Date:  2004-08       Impact factor: 4.398

7.  Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.

Authors:  Tobias Larsson; Ulf Nisbeth; Osten Ljunggren; Harald Jüppner; Kenneth B Jonsson
Journal:  Kidney Int       Date:  2003-12       Impact factor: 10.612

8.  Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.

Authors:  Takashi Shimada; Makoto Kakitani; Yuji Yamazaki; Hisashi Hasegawa; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Kazuma Tomizuka; Takeyoshi Yamashita
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

9.  Differential effects of Npt2a gene ablation and X-linked Hyp mutation on renal expression of Npt2c.

Authors:  Harriet S Tenenhouse; Josée Martel; Claude Gauthier; Hiroko Segawa; Ken-ichi Miyamoto
Journal:  Am J Physiol Renal Physiol       Date:  2003-09-02

10.  Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.

Authors:  Tobias Larsson; Richard Marsell; Ernestina Schipani; Claes Ohlsson; Osten Ljunggren; Harriet S Tenenhouse; Harald Jüppner; Kenneth B Jonsson
Journal:  Endocrinology       Date:  2004-02-26       Impact factor: 4.736

View more
  72 in total

1.  Cholesterol in vascular and valvular calcification.

Authors:  L L Demer
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

2.  Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372.

Authors:  Mohammed S Razzaque
Journal:  Expert Opin Ther Pat       Date:  2010-07       Impact factor: 6.674

3.  Using Linear Discriminant Analysis to Characterize Novel Single Nucleotide Polymorphisms and Expression Profile Changes in Genes of Three Breeds of Rabbit (Oryctolagus cuniculus).

Authors:  Ahmed I Ateya; Basma M Hendam; Hend A Radwan; Eman A Abo Elfadl; Mona M Al-Sharif
Journal:  Comp Med       Date:  2021-05-25       Impact factor: 0.982

4.  Klotho and Na+,K+-ATPase activity: solving the calcium metabolism dilemma?

Authors:  M Shawkat Razzaque
Journal:  Nephrol Dial Transplant       Date:  2007-10-31       Impact factor: 5.992

Review 5.  Does FGF23 toxicity influence the outcome of chronic kidney disease?

Authors:  Mohammed Shawkat Razzaque
Journal:  Nephrol Dial Transplant       Date:  2008-11-07       Impact factor: 5.992

Review 6.  Genetics of Refractory Rickets: Identification of Novel PHEX Mutations in Indian Patients and a Literature Update.

Authors:  Binata Marik; Arvind Bagga; Aditi Sinha; Pankaj Hari; Arundhati Sharma
Journal:  J Pediatr Genet       Date:  2018-01-28

Review 7.  Vascular calcification: pathobiology of a multifaceted disease.

Authors:  Linda L Demer; Yin Tintut
Journal:  Circulation       Date:  2008-06-03       Impact factor: 29.690

8.  FGF23-induced hypophosphatemia persists in Hyp mice deficient in the WNT coreceptor Lrp6.

Authors:  Kazuyoshi Uchihashi; Teruyo Nakatani; Regina Goetz; Moosa Mohammadi; Xi He; Mohammed S Razzaque
Journal:  Contrib Nephrol       Date:  2013-05-03       Impact factor: 1.580

9.  Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse.

Authors:  Catherine A Brownstein; Junhui Zhang; Althea Stillman; Bruce Ellis; Nancy Troiano; Douglas J Adams; Caren M Gundberg; Richard P Lifton; Thomas O Carpenter
Journal:  Endocrinology       Date:  2009-12-01       Impact factor: 4.736

10.  A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.

Authors:  C E Dumitrescu; M H Kelly; A Khosravi; T C Hart; J Brahim; K E White; E G Farrow; M H Nathan; M D Murphey; M T Collins
Journal:  Osteoporos Int       Date:  2008-11-04       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.